Summary
0.84 0.05(6.05%)05/20/2024
Gritstone Oncology Inc (GRTS)
Gritstone Oncology Inc (GRTS)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 4.76 | 26.20 | -0.98 | -52.36 | -44.81 | -58.61 | -90.55 | -92.91 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 1.01 | |
| Open | 0.97 | |
| High | 1.04 | |
| Low | 0.95 | |
| Volume | 1,974,852 | |
| Change | 0.05 | |
| Change % | 4.76 | |
| Avg Volume (20 Days) | 1,958,597 | |
| Volume/Avg Volume (20 Days) Ratio | 1.01 | |
| 52 Week Range | 0.67 - 3.33 | |
| Price vs 52 Week High | -69.67% | |
| Price vs 52 Week Low | 50.75% | |
| Range | 3.72 | |
| Gap Up/Down | 0.00 | |
Fundamentals | ||
| Market Capitalization (Mln) | 85 | |
| EBIDTA | -73,576,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 19.67 | |
| Book Value | 3.2370 | |
| Earnings Per Share | -1.0740 | |
| EPS Estimate Current Quarter | -0.5200 | |
| EPS Estimate Next Quarter | -0.5200 | |
| EPS Estimate Current Year | -1.0600 | |
| EPS Estimate Next Year | -1.7700 | |
| Diluted EPS (TTM) | -1.0740 | |
| Revenues | ||
| Profit Marging | -1.5587 | |
| Operating Marging (TTM) | -1.5607 | |
| Return on asset (TTM) | -0.2304 | |
| Return on equity (TTM) | -0.5178 | |
| Revenue TTM | 46,499,000 | |
| Revenue per share TTM | 0.6890 | |
| Quarterly Revenue Growth (YOY) | 1.7840 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -84,606,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 3.9428 | |
| Revenue Enterprise Value | 13.9263 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 67,987,800 | |
| Shares Float | 45,151,394 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 3.38 | |
| Institutions (%) | 62.91 | |
05/02 16:05 EST - globenewswire.com
Gritstone bio to Report First Quarter 2024 Financial Results and Provide Corporate Updates on May 9, 2024
-- Conference call and webcast to begin at 4:30pm ET -- EMERYVILLE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced it will report financial results for the first quarter 2024 and provide corporate updates after market close on Thursday, May 9, 2024. The announcement will be followed by a conference call and audio webcast, which will begin at 4:30pm ET.
Gritstone bio to Report First Quarter 2024 Financial Results and Provide Corporate Updates on May 9, 2024
-- Conference call and webcast to begin at 4:30pm ET -- EMERYVILLE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced it will report financial results for the first quarter 2024 and provide corporate updates after market close on Thursday, May 9, 2024. The announcement will be followed by a conference call and audio webcast, which will begin at 4:30pm ET.
05/02 11:06 EST - zacks.com
Gritstone bio Inc. (GRTS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Gritstone bio (GRTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gritstone bio Inc. (GRTS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Gritstone bio (GRTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
04/29 07:00 EST - globenewswire.com
Gritstone bio Announces Appointment of Stephen Webster to its Board of Directors
EMERYVILLE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced the appointment of Stephen Webster to its Board of Directors. A veteran finance executive in the biotechnology industry, Mr. Webster has served as an executive for several renowned companies and held key roles in raising capital, business development transactions and operations for over 30 years. The company also announced that Steve Krognes will not stand for re-election at the 2024 Annual Meeting.
Gritstone bio Announces Appointment of Stephen Webster to its Board of Directors
EMERYVILLE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced the appointment of Stephen Webster to its Board of Directors. A veteran finance executive in the biotechnology industry, Mr. Webster has served as an executive for several renowned companies and held key roles in raising capital, business development transactions and operations for over 30 years. The company also announced that Steve Krognes will not stand for re-election at the 2024 Annual Meeting.
04/20 12:15 EST - prnewswire.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS
NEW YORK , April 20, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gritstone bio, Inc. ("Gritstone" or the "Company") (NASDAQ: GRTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS
NEW YORK , April 20, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gritstone bio, Inc. ("Gritstone" or the "Company") (NASDAQ: GRTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
04/15 07:00 EST - globenewswire.com
Nature Medicine Publishes Interim Results from Gritstone bio's Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)
-- Paper details vaccine design optimization process of Gritstone's “off-the-shelf” or shared neoantigen vaccine platform, SLATE -- -- Discovery of a novel immunodominance hierarchy of tumor neoantigens (including KRAS) enabled the development of a more potent, KRAS-specific vaccine candidate (SLATE-KRAS) being studied by Steven A. Rosenberg of the National Cancer Institute (NCI) --
Nature Medicine Publishes Interim Results from Gritstone bio's Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)
-- Paper details vaccine design optimization process of Gritstone's “off-the-shelf” or shared neoantigen vaccine platform, SLATE -- -- Discovery of a novel immunodominance hierarchy of tumor neoantigens (including KRAS) enabled the development of a more potent, KRAS-specific vaccine candidate (SLATE-KRAS) being studied by Steven A. Rosenberg of the National Cancer Institute (NCI) --
04/08 10:35 EST - zacks.com
Down -63.39% in 4 Weeks, Here's Why Gritstone bio (GRTS) Looks Ripe for a Turnaround
Gritstone bio (GRTS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Down -63.39% in 4 Weeks, Here's Why Gritstone bio (GRTS) Looks Ripe for a Turnaround
Gritstone bio (GRTS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
04/07 00:22 EST - seekingalpha.com
Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering
Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering
Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering
Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering
04/04 14:36 EST - zacks.com
Gritstone (GRTS) Plummets 58% in a Week: Here's Why
Gritstone (GRTS) plunges after a mid-stage study evaluating its personalized cancer vaccine in certain patients with colorectal cancer failed to achieve its primary endpoint.
Gritstone (GRTS) Plummets 58% in a Week: Here's Why
Gritstone (GRTS) plunges after a mid-stage study evaluating its personalized cancer vaccine in certain patients with colorectal cancer failed to achieve its primary endpoint.
04/02 10:29 EST - investorplace.com
Why Are Health Insurance Stocks HUM, UNH, CI Down Today?
Health insurance stocks are falling on Tuesday after President Joe Biden's Administration announced it won't increase Medicare Advantage rates for 2025. This comes as a surprise to health insurance companies as the government typically increases its rates compared to its initial proposals.
Why Are Health Insurance Stocks HUM, UNH, CI Down Today?
Health insurance stocks are falling on Tuesday after President Joe Biden's Administration announced it won't increase Medicare Advantage rates for 2025. This comes as a surprise to health insurance companies as the government typically increases its rates compared to its initial proposals.
04/02 09:16 EST - investorplace.com
Why Is Gritstone Bio (GRTS) Stock Down 44% Today?
Gritstone Bio (NASDAQ: GRTS ) stock is falling on Tuesday after the clinical-stage biotechnology company announced the pricing of an underwritten public offering for its shares. This public offering has the company selling 8,333,333 shares of GRTS stock for $1.50 each.
Why Is Gritstone Bio (GRTS) Stock Down 44% Today?
Gritstone Bio (NASDAQ: GRTS ) stock is falling on Tuesday after the clinical-stage biotechnology company announced the pricing of an underwritten public offering for its shares. This public offering has the company selling 8,333,333 shares of GRTS stock for $1.50 each.
04/01 23:00 EST - globenewswire.com
Gritstone bio Announces Pricing of $32.5 Million Underwritten Public Offering
EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced the pricing of an approximately $32.5 million underwritten public offering of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying common warrants to purchase common stock (or pre-funded warrants to purchase common stock in lieu thereof), before deducting underwriting discounts and commissions and offering expenses.
Gritstone bio Announces Pricing of $32.5 Million Underwritten Public Offering
EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced the pricing of an approximately $32.5 million underwritten public offering of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying common warrants to purchase common stock (or pre-funded warrants to purchase common stock in lieu thereof), before deducting underwriting discounts and commissions and offering expenses.
04/01 16:10 EST - globenewswire.com
Gritstone bio Announces Proposed Public Offering
EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced that it has commenced an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying common warrants to purchase common stock (or pre-funded warrants to purchase common stock in lieu thereof). All of the shares of common stock, pre-funded warrants and accompanying common warrants are being offered by Gritstone bio. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Gritstone bio Announces Proposed Public Offering
EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced that it has commenced an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying common warrants to purchase common stock (or pre-funded warrants to purchase common stock in lieu thereof). All of the shares of common stock, pre-funded warrants and accompanying common warrants are being offered by Gritstone bio. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
04/01 16:01 EST - globenewswire.com
Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
-- Early progression-free survival (PFS) trends favor GRANITE recipients with hazard ratios of 0.82 in the overall population ([95% CI, 0.34-1.67]; 62% censored) and 0.52 (48% relative risk reduction of progression or death with GRANITE vs. control) in a high-risk group, where clinical data are more mature ([95% CI, 0.15-1.38]; 44% censored); >90% of high-risk patients have liver metastases -- -- Short-term molecular response (as defined by protocol) is uninformative due to an unexpectedly persistent ctDNA drop beyond induction chemotherapy; long-term circulating tumor DNA (ctDNA) responses align with PFS trends and favor GRANITE vs. control patients --
Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
-- Early progression-free survival (PFS) trends favor GRANITE recipients with hazard ratios of 0.82 in the overall population ([95% CI, 0.34-1.67]; 62% censored) and 0.52 (48% relative risk reduction of progression or death with GRANITE vs. control) in a high-risk group, where clinical data are more mature ([95% CI, 0.15-1.38]; 44% censored); >90% of high-risk patients have liver metastases -- -- Short-term molecular response (as defined by protocol) is uninformative due to an unexpectedly persistent ctDNA drop beyond induction chemotherapy; long-term circulating tumor DNA (ctDNA) responses align with PFS trends and favor GRANITE vs. control patients --
03/19 14:49 EST - investorplace.com
3 Speculative Stocks You Can Buy for $3 or Less
The central idea behind cheap speculative stocks under $3 is simple: small-capitalization investments may lever a greater potential for outsized returns. Of course, that depends greatly on the stars aligning perfectly, which rarely happens.
3 Speculative Stocks You Can Buy for $3 or Less
The central idea behind cheap speculative stocks under $3 is simple: small-capitalization investments may lever a greater potential for outsized returns. Of course, that depends greatly on the stars aligning perfectly, which rarely happens.
03/08 07:30 EST - accesswire.com
Did Gritstone bio, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate – GRTS
NEW YORK, NY / ACCESSWIRE / March 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Gritstone bio, Inc. ("Gritstone") (NASDAQ:GRTS) concerning possible violations of federal securities laws. Gritstone issued a press release, on February 29, 2024, "announc[ing] an approximately 40% reduction of its workforce", stating that "[t]he move comes following the recently announced delay of the proposed CORAL Phase 2b study, which resulted in Gritstone not receiving external funding it previously anticipated beginning in 1Q 2024, associated with the initiation of the study.
Did Gritstone bio, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate – GRTS
NEW YORK, NY / ACCESSWIRE / March 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Gritstone bio, Inc. ("Gritstone") (NASDAQ:GRTS) concerning possible violations of federal securities laws. Gritstone issued a press release, on February 29, 2024, "announc[ing] an approximately 40% reduction of its workforce", stating that "[t]he move comes following the recently announced delay of the proposed CORAL Phase 2b study, which resulted in Gritstone not receiving external funding it previously anticipated beginning in 1Q 2024, associated with the initiation of the study.
03/07 07:25 EST - accesswire.com
Levi & Korsinsky Announces an Investigation on Behalf of Gritstone bio, Inc. (GRTS) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / March 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Gritstone bio, Inc. ("Gritstone") (NASDAQ:GRTS) concerning possible violations of federal securities laws. Gritstone issued a press release, on February 29, 2024, "announc[ing] an approximately 40% reduction of its workforce", stating that "[t]he move comes following the recently announced delay of the proposed CORAL Phase 2b study, which resulted in Gritstone not receiving external funding it previously anticipated beginning in 1Q 2024, associated with the initiation of the study.
Levi & Korsinsky Announces an Investigation on Behalf of Gritstone bio, Inc. (GRTS) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / March 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Gritstone bio, Inc. ("Gritstone") (NASDAQ:GRTS) concerning possible violations of federal securities laws. Gritstone issued a press release, on February 29, 2024, "announc[ing] an approximately 40% reduction of its workforce", stating that "[t]he move comes following the recently announced delay of the proposed CORAL Phase 2b study, which resulted in Gritstone not receiving external funding it previously anticipated beginning in 1Q 2024, associated with the initiation of the study.
03/05 19:46 EST - zacks.com
Gritstone bio Inc. (GRTS) Reports Q4 Loss, Tops Revenue Estimates
Gritstone bio Inc. (GRTS) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.30 per share a year ago.
Gritstone bio Inc. (GRTS) Reports Q4 Loss, Tops Revenue Estimates
Gritstone bio Inc. (GRTS) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.30 per share a year ago.